Investing
Sanofi-Aventis (SNY) Withdraws Drug Which Can Cause Suicidal Thinking
Published:
Sanofi-Aventis (SNY) is withdrawing its application to sell its drug rimonabant in the US as a treatment for obesity. The drug has been found to have psychiatric sides effects. This may include suicidal thinking.
According to The Wall Street Journal: "By withdrawing its application, Sanofi is hoping to avoid an outright rejection of the drug by the FDA, which was set to rule by the end of July, analysts said." If the drug does cause thinking it is difficult to see why the company would mind a rejection.
But, Big Pharma’s work is never done. The WSJ adds: "Ben Yeoh, a pharmaceutical analyst with Dresdner Kleinwort in London, said the company may be thinking of resubmitting rimonabant as a diabetes treatment."
Perhaps people with diabetes are less likely than those who are corpulent to think about killing themselves.
Douglas A. McIntyre can be reached at [email protected].
Get Ready To Retire (Sponsored)
Start by taking a quick retirement quiz from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes, or less.
Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.
Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future
Get started right here.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
